ERBB2 and ductal breast carcinoma in situ: In an early phase clinical trial, a total of 54 patients with either HER2+ DCIS or invasive breast cancer received 6 weekly intratumoral and/or intranodal injections of DC1 vaccines pulsed ex vivo with 6 distinct MHC class II HER218.